๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

The cost of treating immune thrombocytopenic purpura using intravenous Rh immune globulin versus intravenous immune globulin

โœ Scribed by Sandler, S. Gerald; Novak, Sharon C.; Roland, Barbara

Publisher
John Wiley and Sons
Year
2000
Tongue
English
Weight
18 KB
Volume
63
Category
Article
ISSN
0361-8609

No coin nor oath required. For personal study only.

โœฆ Synopsis

Multiple factors, including efficacy, toxicity and cost, may influence the decision to treat immune thrombocytopenic purpura (ITP) with intravenous immune globulin (IVIG) or intravenous Rho (D) immune globulin (IV RhIG). We conducted a survey of 50 hospitals in 31 states to determine the costs for treating ITP using conventional doses for IVIG or IV RhIG, based on package insert recommendations. The average cost for a dose of IVIG ($2,771) was 71.7% ($1,157) more than that for a dose of IV RhIG ($1,614). In the absence of clearly defined differences in clinical outcomes when treating ITP with IVIG or IV RhIG, the difference in cost may be an important factor in selecting the treatment.

๐Ÿ“œ SIMILAR VOLUMES

Successful prevention of post-transfusio
Successful prevention of post-transfusion Rh alloimmunization by intravenous Rho (D) immune globulin (WinRho SD)
โœ Anderson, Barry; Shad, Aziza T.; Gootenberg, Joseph E.; Sandler, S. Gerald ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 18 KB ๐Ÿ‘ 1 views

Alloimmunization to the D blood group antigen following the transfusion of D-positive red blood cells to a D-negative recipient may be prevented in most persons by a prompt and adequate dose of Rho (D) immune globulin (RhIG). Until recently, the only RhIG approved by the US Food and Drug Administrat